1. Introduction {#sec1}
===============

NET is derived from the embryonal neural crest cells called Argentaffin or Kulchitsky cells and have a potential for secreting serotonin. This tumor can arise anywhere in the distribution of the Argentaffin cell system. In addition to the most common sites of occurrence, namely, ileum and appendix these tumors have reported to occur in bladder, prostate, rectum, stomach, bronchi, pancreas, and biliary tree.

Primary Biliary Tract NETs are rare and account for 0.2%--2% \[[@B1], [@B2]\] of all gastrointestinal neuroendocrine tumors.

The Literature documents about 77 cases of neuroendocrine tumor arising from the biliary tree which includes common bile duct, common hepatic duct, cystic duct, and hilar confluence.

We report a case of Primary Biliary NET arising from the left hepatic duct. An extensive search of the literature has yielded no reference regarding a NET arising from the left Hepatic ducts. The present case is the first reported case of a NET arising in the left hepatic duct.

2. Case Report {#sec2}
==============

A 69-years-old female presented with colicky pain in the right hypochondrium since 3 years. She had past history of open cholecystectomy done for gall stones 15 years back. On physical examination the patient was anicteric with soft abdomen. An Ultrasonography (USG) of the abdomen showed a hypoechoic lesion of size 3.5 cm × 4 cm in segment 4 of the liver. Computerized Tomography (CT) of the abdomen showed a 4.1 × 3.7 cm heterogeneously enhancing mass lesion in segment IV of liver abutting the left branch of portal vein ([Figure 1](#fig1){ref-type="fig"}). A Magnetic Resonance Imaging (MRI) of upper abdomen with Magnetic Resonance CholagioPancreaticography (MRCP) showed a filling defect in the left hepatic duct with lesion in the adjacent part of liver in segment IV, suggestive of a left hepatic duct tumor with infiltration in the liver ([Figure 2](#fig2){ref-type="fig"}). Tumor marker serum alfa fetoprotein was mildly raised. Patient was worked up for left hepatectomy. Intraopertaively a lesion arising from the left hepatic duct involving the left branch of portal vein and extending upto the portal confluence was found ([Figure 3](#fig3){ref-type="fig"}) rendering the tumor unresectable. A biopsy was taken from the mass and procedure was abandoned in view of inoperability. Histopathology showed typical rosette appearance of a neuroendocrine tumor ([Figure 4](#fig4){ref-type="fig"}) and immunohistochemistry positive for CD56, Chromogranin and Synaptophysin ([Figure 5](#fig5){ref-type="fig"}). Ultrastructural study of the cell with electron microscopy ([Figure 6](#fig6){ref-type="fig"}) showed the presence of multiple neurosecretory granules with muscle tissue.

A whole body Positron Emission Tomography (PET) scan and an Octreotride labeled radionulceotide scan showed somatostatin receptor expressing lesion in the hepatobiliary system ([Figure 7](#fig7){ref-type="fig"}).

The patient was started on long-acting Octreotride therapy single dose every month. The patient has received 12 of such doses and is doing well after a 1-year followup without any complications. A follow up MRI ([Figure 8](#fig8){ref-type="fig"}) upper abdomen with MRCP at 1 year showed the absence of filling defect in the Left hepatic duct that was seen previously which showed tumor regression.

3. Discussion {#sec3}
=============

Primary Biliary-tract NETs are very rare. They account for 0.2--2% of all gastrointestinal NET \[[@B1], [@B2]\] reason being the paucity of enterochromaffin cells from which NETs arise in this area. Chronic inflammation of the bile duct epithelium is responsible for metaplasia of these enterochromaffin cells and formation of NET.

Davies \[[@B3]\] in 1959 reported NET of the distal bile duct and pancreatic duct which represented more of a periampullary NET rather than a biliary tract. Pilz \[[@B4]\] in 1961 was credited to report the first case of a Biliary Tract NET. After an extensive search of the Medline only 77 cases of Biliary Tract NET have been reported so far in the literature since 1961 ([Table 1](#tab1){ref-type="table"}).

Till now no NET in the literature has been reported in the isolated left hepatic duct possibly making our case the first reported case of an isolated left hepatic duct NET.

The most common site of malignancy in the biliary tract was common bile duct (57.14%) followed by the hilar confluence (27.28%), the cystic duct (9.1%), common hepatic duct (5.12%) and finally the left hepatic duct (1.23%).

The mean age of presentation was 47 years (range 6 years to 79 years).

The male to female ratio is 1 : 1.23 showing that the biliary NET has a preponderance for female.

By far the most common symptom in patients of Biliary tract NET is Jaundice (63.4%) followed by Pain (14.1%), jaundice with pain (12.7%) and remaining nonspecific symptoms like weight loss.

The incidence of a Carcinoid syndrome in patients of Biliary Tract NET is very rare. Only 4 cases which include a single case published by Nesi et al. \[[@B52]\] in 2006 with symptoms of diarrhea due to secretion of serotonin and 3 cases by Price et al. \[[@B66]\] in 2009 with features of Zollinger Ellison syndrome due to secretion of gastrin from tumor in CBD.

4. Conclusion {#sec4}
=============

Biliary Tract NET are rare tumors that typically present with jaundice and pain. As compared to its counterpart Cholangiocarcinoma Biliary NET occurs in a younger age group with a female preponderance \[[@B40]\]. Biliary NET usually are nonsecreting tumor. Preoperative diagnosis of these tumors require a high index of suspicion and accurate histopathological diagnosis which must include a immunohistochemistry study and electron microscopy. Biliary tract NET are slow-growing indolent tumor which have a limited propensity for local and metastatic spread. Surgical resection aimed at complete tumor excision with bilio-enteric continuity offers the best cure and high survival rates. Patients who have undergone resection have a long term survival. Even in inoperable patients chemotherapy with newer biologic agents like Octreotride have a favorable outcome on the patient\'s survival.
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![CT scan showing mass lesion in segment 4 abutting the left branch of portal vein.](CRIM.SURGERY2012-786432.001){#fig1}

![MRCP showing a filling defect in the left hepatic duct.](CRIM.SURGERY2012-786432.002){#fig2}

![Intraoperative picture showing tumor arising from the left hepatic duct. CBD hooked in yellow, hepatic artery in red, and portal vein in blue.](CRIM.SURGERY2012-786432.003){#fig3}

![Histopathology showing a typical rosette appearance of neuroendocrine tumor.](CRIM.SURGERY2012-786432.004){#fig4}

![Immunohistochemistry staining positive for Chromogranin (a) and Synaptophysin (b).](CRIM.SURGERY2012-786432.005){#fig5}

![Electron microscopy picture showing multiple granules of varying sizes.](CRIM.SURGERY2012-786432.006){#fig6}

![PET Scan (a) and Octreotride labelled (b) scan showing tumor limited to the hepatobiliary system.](CRIM.SURGERY2012-786432.007){#fig7}

![Follow up MRCP at 1 year showing absence of any filling defect in the left hepatic duct.](CRIM.SURGERY2012-786432.008){#fig8}

###### 

Showing study of reported cases of Biliary tract NET.

  No.      Case reference                             Age   Sex   Complaint             Location
  -------- ------------------------------------------ ----- ----- --------------------- -------------------
  \(1\)    Pilz, \[[@B4]\] 1961                       55    F     Weakness              CBD
  \(2\)    Little et al., \[[@B6]\] 1968              41    F     RUQ pain, jaundice,   Hilar
  \(3\)    Bergdahl, \[[@B7]\] 1976                   79    F     Autopsy finding       Distal CBD
  \(4\)    Judge et al., \[[@B8]\] 1976               19    M     Jaundice, pain        Hilar
  \(5\)    Gerlock and Muhletaler \[[@B9]\] 1979      32    M     Jaundice              CBD
  \(6\)    Vitaux et al., \[[@B10]\] 1981             24    M     Jaundice              Distal CBD
  \(7\)    Nakamuara et al. \[[@B11]\] 1981           58    F     Jaundice              CBD
  \(8\)    Abe et al., \[[@B12]\] 1983                64    M     RUQ pain              CBD
  \(9\)    Goodman et al., \[[@B13]\] 1984            28    F     RUQ Pain              Cystic duct
  \(10\)   Jutte et al., \[[@B14]\] 1986              62    M     Back Pain             CHD
  \(11\)   Nicolescu and Popescu, \[[@B15]\] 1986     50    F     RUQ pain              CBD
  \(12\)   Alexander et al., \[[@B16a]\] 1986         64    F     Hematemesis           CBD
  \(13\)   Gastinger et al. \[[@B16b]\] 1987          65    F     Jaundice, Pain        Hilar
  \(14\)   Reinhardt et al. \[[@B17]\] 1988           71    F     Jaundice, fever       CBD
  \(15\)   Chittal and Ra, \[[@B18]\] 1989            46    F     RUQ pain              Cystic duct
  \(16\)   Fujita et al., \[[@B19]\] 1989             55    F     RUQ pain              CBD
  \(17\)   Bickerstaff and Ross \[[@B20]\] 1989       57    F     Jaundice              CBD
  \(18\)   Brown et al., \[[@B21]\] 1990              35    F     Jaundice              Hilar
  \(19\)   Bumin et al., \[[@B22]\] 1990              38    F     Jaundice              CBD
  \(20\)   Fellows et al. \[[@B23]\] 1990             30    M     Jaundice              CBD
  \(21\)   Besznyák et al. \[[@B24]\]                 13    F     Jaundice              Hilar
  \(22\)   Angeles-Angeles et al., \[[@B25]\] 1991    39    F     Jaundice              CBD
  \(23\)   Barron-Rodriguez et al., \[[@B26]\] 1991   36    M     Jaundice, RUQ pain    CBD
  \(24\)   Newman et al., 1992 \[[@B27]\]             15    F     N/A                   CBD
  \(25\)   Dixon et al., 1992 \[[@B28]\]              60    F     RUQ pain              CBD
  \(26\)   Rugge et al., \[[@B29]\] 1992              64    F     Jaundice, RUQ pain    Cysticduct, CBD
  \(27\)   Gembala et al., \[[@B30]\] 1993            28    M     Jaundice              Hilar
  \(28\)   Mandujano-Vera et al., \[[@B31]\] 1995     53    F     Jaundice              CBD
  \(29\)   Sankary et al., \[[@B33]\] 1995            47    F     Jaundice              Hilar
  \(30\)   Hao et al., \[[@B34]\] 1996                47    M     Incidental finding    CBD
  \(31\)   Kopelman et al., \[[@B35]\] 1996           44    M     Jaundice              CBD
  \(32\)   Belli et al., \[[@B36]\] 1996 CBD          78    M     Jaundice              CBD
  \(33\)   Bembenek et al., \[[@B37]\] 1998           12    F     Jaundice              Hilar
  \(34\)   Nahas et al., \[[@B38]\] 1998              61    F     Jaundice              Hilar
  \(35\)   Ross et al., \[[@B39]\] 1999               65    F     Jaundice              CBD
  \(36\)   Chamberlain and Blumgart \[[@B40]\] 1999   37    F     Itching               Hilar
  \(37\)   Chamberlain and Blumgart \[[@B40]\] 1999   67    F     Itching               Hilar
  \(38\)   Hermina et al., \[[@B41]\] 1999            69    M     RUQ pain              Cystic duct
  \(39\)   Perakath et al. \[42\] 1999                36    F     Jaundice, Pain        CHD
  \(40\)   Chan et al \[[@B42]\] 2000                 14    M     Jaundice              Hilar
  \(41\)   Maitra et al., \[[@B43]\] 2000             53    F     Jaundice,             CBD
  \(42\)   Maitra et al., \[[@B43]\] 2000             61    F     Jaundice, itching     Hilar
  \(43\)   Juturi et al., \[[@B44]\] 2000             43    M     Jaundice, itching     CBD
  \(44\)   Turrión et al., \[[@B45]\] 2002            51    F     Jaundice, itching     Hilar
  \(45\)   Pawlik et al., \[[@B46]\] 2003             59    M     Jaundice              Hilar
  \(46\)   Podnos et al., \[[@B47]\] 2003             65    F     Cholecystitis         CBD
  \(47\)   Podnos et al., \[[@B47]\] 2003             27    M     Jaundice, itching     CBD
  \(48\)   Volpe et al., \[[@B48]\] 2003              19    M     Jaundice, pain        CBD
  \(49\)   Menezes et al., \[[@B49]\]                 30    M     Jaundice              CHD
  \(50\)   Ligato et al., \[[@B50]\] 2005             33    F     Irritable bowel       Hilar
  \(51\)   Hubert et al., \[[@B51]\] 2005             NA    M     Jaundice              CBD
  \(52\)   Hubert et al., \[[@B51]\] 2005             NA    M     Jaundice              CBD
  \(53\)   Hubert et al., \[[@B51]\] 2005             NA    F     Jaundice              CBD
  \(54\)   Nesi et al., \[[@B52]\] 2006               30    M     Jaundice, iarrhoea    CBD
  \(55\)   Kim et al., \[[@B53]\] 2006                67    F     Jaundice              CBD
  \(56\)   Caglikulekci et al., \[[@B54]\] 2006       40    F     Jaundice              Hilar
  \(57\)   Honda et al., \[[@B55]\] 2006              76    M     Jaundice, pain        CBD
  \(58\)   Todorki et al., \[[@B56]\] 2007            73    M     Jaundice, Fever       CBD
  \(59\)   Sethi et al., \[[@B57]\] 2007              51    M     ERCP finding          CHD with Cystic
  \(60\)   Stavridi et al., \[[@B58]\] 2007           NA    NA    NA                    Cystic duct
  \(61\)   Jiménez et al., \[[@B59]\] 2007            60    M     Jaundice              Hilar
  \(62\)   Ferrone et al., \[[@B60]\] 2007            NA    NA    NA                    NA
  \(63\)   Nafidi et al., \[[@B61]\] 2008             31    F     RUQ pain              CBD
  \(64\)   Gusani et al., \[[@B62]\] 2008             NA    NA    NA                    CBD
  \(65\)   Schmitt et al., \[[@B63]\] 2008            NA    NA    NA                    Hilar
  \(66\)   Costantini et al., \[[@B64]\] 2008         NA    NA    NA                    CHD
  \(67\)   Felekouras et al., \[[@B65]\] 2009         60    F     Jaundice              Cystic duct
  \(68\)   Price et al., \[[@B66]\] 2009              NA    NA    Jaundice              CBD
  \(69\)   Price et al., \[[@B66]\] 2009              NA    NA    Jaundice              CBD
  \(70\)   Price et al., \[[@B66]\] 2009              NA    NA    Jaundice              Hilar
  \(71\)   Tonnhofer et al., \[[@B67]\]               6     F     Jaundice              CBD
  \(72\)   Zhan et al. \[[@B68]\] 2010                10    M     NA                    CBD
  \(73\)   Squillaci et al., \[[@B69]\] 2010          52    M     Jaundice              CBD
  \(74\)   Squillaci et al., \[[@B69]\] 2010          70    M     Jaundice              CBD
  \(75\)   Tsalis et al., \[[@B70]\] 2010             77    M     Incidental            Hilar
  \(76\)   Lee et al., \[[@B71]\] 2011                59    M     Jaundice              CBD
  \(77\)   Athanasopoulos et al., \[[@B72]\] 2011     43    M     Jaundice              CBD
  \(78\)   Present case                               69    F     Pain                  Left hepatic duct

CHD: common hepatic duct, CBD: common bile duct, Hilar at the common bile duct bifurcation.
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